SLC6A3 and neurodegenerative disease: Advanced diagnostic modalities, such as dopamine transporter SPECT and myocardial scintigraphy, have demonstrated utility in distinguishing very late-onset schizophrenia (VLOS) from neurodegenerative diseases like dementia with Lewy bodies (DLB).